Evaluation of Alzheimer's disease using an independent component analysis of an individual's resting-state functional MRI

• US 20050215884A1
• Filed: 02/25/2005
• Published: 09/29/2005
• Est. Priority Date: 02/27/2004
• Status: Abandoned Application

• Current Assignee: Allan L. Reiss, Michael D. Greicius, Vinod Menon
• Original Assignee: Allan L. Reiss, Michael D. Greicius, Vinod Menon
• Inventors: Menon, Vinod, Greicius, Michael D., Reiss, Allan L.
• Application Number:
  US11/067,612
• Publication Number:
  US 20050215884A1
• Time in Patent Office: Days
• US Class Current: 600/410
• CPC Class Codes: A61B 5/055 involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• CPC Class Codes: A61B 5/4088 Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia

Abstract

A clinically valuable method is provided for evaluating the onset or progression of Alzheimer'"'"'s disease using a non-invasive biomarker obtained from an independent component analysis (ICA) of an individual'"'"'s resting state functional MRI. The method is relatively more automated and objective than previous methods and exploits dysfunctional connectivity across an entire network of brain regions in Alzheimer'"'"'s disease. It eliminates the need for investigator'"'"'s intervention as much as possible and is more robust than structural and functional methods targeting the hippocampus.

Claims

1. A method of evaluating the onset or progression of Alzheimer'"'"'s disease using a non-invasive clinical marker obtained from an independent component analysis of an individual'"'"'s resting state functional MRI, comprising the steps of:

(a) matching n components of said independent component analysis of said individual'"'"'s resting state functional MRI with a reference template representing a default-mode network;

(b) assigning a goodness-of-fit score to said matched n components;

(c) selecting the component with the highest score from said goodness-of-fit scores as the default-mode network component for said individual'"'"'s resting state functional MRI;

(d) determining said non-invasive clinical marker by comparing the score of said default-mode network component with reference values; and

(e) evaluating for said individual an onset or progression of Alzheimer'"'"'s disease using said non-invasive clinical marker.

2. The method as set forth in claim 1, wherein said reference values are goodness-of-fit scores of default-mode networks in healthy or normal individuals, individuals with non-Alzheimer'"'"'s dementias, individuals with Alzheimer'"'"'s disease, or individuals with mild cognitive impairment.

3. The method as set forth in claim 1, wherein said non-invasive clinical marker reflects the probability of said individual having or developing Alzheimer'"'"'s disease.

4. The method as set forth in claim 1, wherein said matching includes a nonlinear template-matching method, a linear template-matching method, a weighted template-matching method or a binary template-matching method.